CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 11 No. 12
Pages: 1  2  
Next
 

Promoting Smoking Cessation Among Cancer Patients: A Behavioral Model

By

Alexander V. Prokhorov, MD, PhD, and Ellen R. Gritz, PhD
Department of Behavioral Science
Karen Suchanek Hudmon, DrPH, RPh
Departments of Behavioral Science and Epidemiology, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas

| December 1, 1997

The smoking cessation clinical practice guideline recently published by the Agency for Health Care Policy and Research (AHCPR) summarizes current knowledge on smoking cessation treatments. Among its recommendations, the guideline encourages physicians to motivate patients who indicate that they are not yet ready to quit smoking. Because medical training typically emphasizes pharmacologic rather than behavioral treatment, we believe that physicians caring for cancer patients may benefit from more extensive instruction in motivating patients to quit smoking. This article describes how a contemporary theoretical approach, the transtheoretical model of change, can be used to promote behavioral change. Multiple studies, primarily in the field of smoking cessation, provide strong empiric support for use of this model in clinical practice. The model consists of five stages of smoking cessation that describe different levels of readiness to quit: precontemplation, contemplation, preparation, action, and maintenance. A diagnostic tool is presented, and specific smoking cessation counseling strategies are suggested for each stage of change. Implications for the use of the model by physicians who counsel and treat smokers are discussed. [ONCOLOGY 11(12): 1807-1813, 1997]



Introduction

Cigarette smoking is a dominant, preventable cause of morbidity and mortality in the United States,[1] accounting for more than 419,000 deaths each year. More than 150,000 of these deaths occur as a result of neoplasms.[2] In 1993, an estimated 25% of adults in the United States were current smokers,[3] and smoking-attributable costs for medical care were estimated to be $50 billion.[4]

Effective and timely administration of smoking cessation interventions can significantly reduce the risk of smoking-related disease.[5] Physicians in general and oncologists in particular can play an important role in providing this type of intervention. Since 70% of smokers see a physician annually,[6,7] there is considerable opportunity for smoking cessation counseling by health-care providers. Even a very brief intervention provided by a health care professional appears to increase smoking cessation, and a physician’s strong advice to quit increases positive outcomes in a remarkably cost-effective way.[8]

The National Cancer Institute (NCI) projects that if 100,000 physicians were to help 10% of their patients who smoke to stop each year, the number of smokers in the United States would decrease by an additional 2 million people annually.[9] Unfortunately, many physicians still underutilize or neglect smoking cessation treatment. The modifiable barriers to delivery of smoking cessation intervention by many health-care providers include absence of necessary skills, limited knowledge of the effectiveness of their own counseling, lack of organizational support in the office environment, and limited availability of materials to aid them and their patients in smoking cessation efforts.[10-12]

In addition, some physicians may have reservations about the relevance of smoking cessation intervention for patients who have types of neoplasms that have not been firmly attributed to smoking (eg, breast cancer). However, the potential benefits of smoking cessation for the majority of cancer patients can be assumed on the basis of compelling evidence obtained from disease-free populations. First, tobacco use may lead to a second primary malignancy, such as lung cancer, for which cancer survivors may be at high risk. Second, smoking can increase the incidence of comorbidity (eg, cardiovascular and/or pulmonary disease) by worsening the course of the disease[13,14] and by reducing the effectiveness of commonly prescribed medications (eg, beta-blockers, bronchodilators, analgesics, benzodiazepines, and phenothiazines).[15] Third, cigarette use may reduce or negatively impact on the patient’s overall quality of life by reducing physical fitness and affecting financial well-being.

Smoking cessation has been shown to improve self-control, self-esteem, and other characteristics of well-being.[5,16] Hence, effective smoking cessation counseling should be incorporated into the cancer treatment plan.

The smoking cessation clinical practice guideline recently published by the Agency for Health Care Policy and Research (AHCPR)[17,18] summarizes current progress in smoking cessation treatment and recommends specific methods to be utilized by health-care providers when counseling and treating patients who smoke. The AHCPR guideline delineates recommendations for: (1) primary-care physicians; (2) tobacco cessation specialists and programs; and (3) health-care administrators, insurers, and purchasers. In the clinician’s section of the guideline, the five steps involved in promoting cessation are outlined: step I entails systematically identifying all smokers; step II, strongly advising all smokers to quit; step III, determining patients’ willingness to make a quit attempt; step IV, motivating patients who are not willing to quit in the immediate future and assisting those who are willing to quit smoking by setting a quit date, offering nicotine(Drug information on nicotine) replacement therapy, and providing self-help materials and skill training; and step V, scheduling a follow-up contact.

The behavioral aspects of smoking cessation treatment are not as relevant to the typical physician’s training as are the pharmacologic aspects (eg, nicotine replacement therapy). Therefore, while fully recognizing the value of the guideline in enhancing outcomes from smoking cessation treatments delivered by health-care providers, this paper focuses on a specific method of behavioral counseling based on the transtheoretical model of change (TTM),[19-21] a promising theoretical approach to helping patients quit smoking. We believe that this approach represents a feasible, effective method that can easily be applied by physicians in a clinical setting.

A Theoretical Approach to Promoting Smoking Cessation Among Cancer Patients

A wide range of social-behavioral theories are available to help explain, predict, and alter human behavior. Typically, health-care providers apply aspects of multiple theories simultaneously when promoting behavioral change.

The TTM, which was developed by combining common theoretical elements identified through the analysis of multiple therapeutic approaches,[19] provides a practical, effective approach to promoting positive health behaviors. Although studied primarily within the context of smoking behavior, the model has demonstrated robustness across various other health behaviors, including weight control, skin cancer prevention, psychological distress, alcohol(Drug information on alcohol) use, exercise, and psychiatric disorders.[22] In the sections below, we describe the model and how it may be applied by physicians to promote smoking cessation among patients with cancer.

An Overview of the TTM

The TTM classifies smoking behavior as a function of five stages of change: (1) precontemplation, (2) contemplation, (3) preparation, (4) action, and (5) maintenance. Generally speaking, the stages reflect an individual’s current disposition about his or her smoking behavior and intent to quit. Movement through the stages is associated with changes in the use of coping activities and shifts in attitudes about smoking, motivation, decision-making, and confidence in quitting. Assessing the stage of change over time enables health-care providers to determine when changes in smoking behavior occur. The model also provides a practical framework for designing interventions and enables providers to select the most appropriate intervention strategies.

Because patients’ dispositions toward quitting vary, “action-oriented” or “just do it” approaches are not appropriate for all patients. Unlike most smoking intervention approaches, TTM-based interventions do not assume that all patients are ready to quit smoking. Instead, the intervention messages and strategies are stage-specific and correspond to the smoker’s readiness to quit. This stage-based approach represents a significant step forward in smoking cessation methods.

Assessing Smoking Status and Stage of Cessation

To effectively reduce smoking among patient populations, smokers first must be identified accurately. Typically, smoking status is assessed using a simple dichotomous-response question, such as “Do you smoke?” Research has shown, however, that altering the way this question is asked can improve disclosure of smoking status, regardless of whether the question is asked orally or is administered as part of a written survey.[23] Specifically, by expanding the response options to enable patients to report on “cutting down,” Mullen et al improved smoking disclosure by 40% in a population of pregnant women.[23]

Modifying the item suggested by Mullen et al[23] to make it more amenable to use of the TTM among cancer patients, we suggest that physicians assess smoking status using the question, “Which of the following statements best describes your cigarette smoking?” As shown in Figure 1, this questions can have multiple answers. The item has a fourth-grade readability level, as measured by the Flesch-Kincaid Readability Test. The question can be included as part of patient registration forms, or the information can be assessed through an interview conducted by the physician or other support staff.

After smoking status is determined, all current and former smokers then should be targeted for a stage-specific smoking intervention, where stage of smoking cessation is assessed as depicted in Figure 1.

  • Precontemplation Stage—In the earliest stage, precontemplation, people are likely to be unaware of the harmful effects of smoking or are unwilling or too discouraged to quit. Being in the precontemplation stage, however, does not necessarily mean that the individuals do not want to quit. Rather, they may have tried to quit, failed, and currently feel frustrated and disappointed about the results.
    Individuals in this stage commonly have experienced few negative consequences associated with smoking; may be defensive about their behavior; and often are not convinced that the negative aspects of smoking outweigh the positive. They are not seriously considering quitting smoking in the next 6 months and, when compared with persons at other stages of change, precontemplators will be the least receptive to cessation interventions. Again, being a precontemplator does not imply that a smoker does not want to quit; rather, it means that the person has no intention of quitting in the foreseeable future.

  • Contemplation Stage—This stage includes current smokers who are seriously considering quitting in the next 6 months and yet have not made a commitment to quit. This group tends to perceive the pros and cons of smoking as approximately equal. It is common for patients to remain in this stage for extended periods, often for years at a time.

  • Preparation Stage—Individuals in the preparation stage are defined as current smokers who are ready to quit smoking in the immediate future (next 30 days) and have made at least one 24-hour quit attempt within the past year. They are taking small but significant steps toward another quit attempt and may have thought about methods for quitting and set a quit date. In general, these smokers are more prepared to take action than are contemplators.

  • Action Stage—This stage encompasses the 6-month period following smoking cessation. During this time, recent quitters are struggling to prevent relapse; thus, they continue to actively modify their habits and environment. This stage requires the most lifestyle changes, and patients may be faced with particularly challenging temptations to smoke in a variety of situations, such as periods of extensive workload or stress, when with others who are smoking, while at social gatherings, and after meals.

  • Maintenance Stage—This stage encompasses the period from 6 months following cessation through the point of termination, where termination is characterized by zero temptation to smoke across all problem situations and maximum confidence in one’s ability to resist relapse. Importantly, individuals in the maintenance stage remain susceptible to relapse and must be continuously aware of environmental and internal stimuli that can cue a return to smoking.
  • Cyclical Nature of the Model—It is a well-known fact that quitting smoking is not necessarily a smooth or easy process. More often than not, long-term change is reached only after repeated attempts,[24,25] with the average smoker making three to four quit attempts before actually becoming a former smoker.[26] When patients relapse, they revert to an earlier stage. Although progression through the stages is required to achieve long-term smoking cessation, the inclusion of the concept of “relapse” requires the model to take on a cyclical property.
    By combining the notion of linear progression with the prospect of recycling through the stages, one obtains a more accurate picture of the process of change. This concept is demonstrated pictorially in Figure 2.
Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

A 48-Year-Old Woman With Irregular Vaginal Bleeding
Brian Morse, MD1 , June 10, 2013

A 48-year-old female presents with complaints of irregular vaginal bleeding and postcoital bleeding. Images from a PET/CT and pelvis MRI reveal characteristic findings. What is your diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
  • ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy
  • Physical Activity Across the Cancer Continuum
  • Exercise After Cancer Diagnosis: Time to Get Moving
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • ASCO: No Benefit From Avastin in Newly Diagnosed Glioblastoma
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy